Pharma: Other News To Note
Friday, March 9, 2012
Shire plc, of Dublin, Ireland, said it received approval through the European decentralized procedure for an oral powder formulation of Fosrenol (lanthanum carbonate), a noncalcium, nonresin phosphate binder, for use in the control of hyperphosphatemia in chronic renal failure patients on hemodialysis or continuous ambulatory peritoneal dialysis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.